Skip to main content
. Author manuscript; available in PMC: 2015 Apr 30.
Published in final edited form as: Sci Transl Med. 2015 Feb 25;7(276):276ra26. doi: 10.1126/scitranslmed.3010101

Fig 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD.

Fig 8

(A) Untreated 24-week-old NPC cats showed significantly fewer Purkinje cells per unit length compared to age-matched normal control cats (*p<0.05). 24-week-old cats receiving 30 mg or greater IC HPβCD showed significantly greater Purkinje cell numbers compared to untreated NPC cats (†p<0.05). In contrast, 24-week-old cats treated postsymptomatically with 120 mg IC HPβCD at 16 weeks of age, showed significantly fewer Purkinje cells compared to normal control cats (*p<0.05). (B) Untreated 24-week-old NPC cats showed no significant difference in hearing threshold compared to normal control cats. In contrast, cats receiving 7.5 mg or 120 mg HPβCD developed significant increases in hearing threshold compared to untreated NPC cats (†<0.05). Individual cats receiving lower doses of HPβCD also showed elevated hearing thresholds although, as a group, these were not significant. (C) At 76 weeks of age, all NPC cats receiving 30 mg or greater HPβCD showed significant elevations in hearing threshold.